cPSA Protéine

N° du produit ABIN935720

Détail du produit

Antigène: cPSA (Complexed Prostate Specific Antigen (cPSA))

Type de proteíne: Native

Origine: Humain

Source: Human

Attributs du produit: Purified native Human PSA/ACT complex protein
Protein Source: Human plasma and seminal fluid

Pureté: > 90 % pure

Information d'application

Indications d'application: Each Investigator should determine their own optimal working dilution for specific applications.

Restrictions: For Research Use only

Stockage

Buffer: 50 mM PBS, pH 7.5, with 0.09 % NaN3.

Agent conservateur: Sodium azide

Précaution d'utilisation: WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.

Stock: -20 °C

Stockage commentaire: Aliquot and store at -20 °C.

Détail du antigène

Antigène: cPSA (Complexed Prostate Specific Antigen (cPSA))

Autre désignation: PSA/ACT complex (cPSA Produits)

Sujet: Prostate Specific Antigen (PSA), a glycoprotein of the glandular kallikrein family, is a serine protease with hymotrypsin-like enzymatic activity, is monitored as increased levels can indicate prostatic neoplasia. PSA released into circulation is present as unbound, free PSA (fPSA) or bound to serum protease inhibitors, such as alpha1-antichymotrypsin (ACT) and alpha2-macroglobulin (A2M). Research indicates that immunoassays for serum levels of PSA alone cannot be relied on to distinguish prostate cancer from benign prostatic hyperplasia (BPH). Serum levels of PSA-ACT complex are reportedly higher in patients with prostate cancer than in those with BPH. As such, measuring the ratio of PSA-ACT to fPSA in patient samples is proving valuable in the differential diagnosis os prostate cancer.
Description: Human plasma and seminal fluid.
Alternative Names: Prostate Specific Antigen/1-antichymotrypsin complex antibody, PSA-ACT complex antibody

Poids moléculaire: 81 kDa